Schizoaffective Disorder, Schizophrenia
Conditions
Keywords
Vitamin D, Schizophrenia, Severely Mentally Ill
Brief summary
Supplementation of Vitamin D in those with low levels will increase the level and result in some improvement in health and psychopathology measures.
Detailed description
Subjects with levels of Vitamin D between 7ng/ml and 30ng/ml will, after signing consent forms, be randomly assigned to either start immediately on Vitamin D for three months or to start after a delay of three months. Those with levels below 7gn/ml will start immediately. All will be evaluated monthly with blood tests, PANSS, movement disorder ratings and information on health and progress from the clinical chart.
Interventions
DIETARY_SUPPLEMENTVitamin D3
50,000 units of Vitamin D3 weekly
Sponsors
Bronx Psychiatric Center
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
19 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Age 19-70, * Schizophrenia or Schizoaffective disorder * stabilized but not expecting to be discharged soon * capacity to give informed consent
Exclusion criteria
* acutely psychotic * acutely medically ill * renal insufficiency * hypercalcemia * hyperparathyroidism
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Psychopathology as measured by the PANSS | 3 months | PANSS is being done every month |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| movement disorder | three months | AIMS (for tardive dyskinesia), Simpson-Angus (for Parkinsonism) and Barnes (for Akathisia) movement disorder rating scales will be completed monthly. |
| General Health | three months | Measured by staff observation and reports, Labs for example glucose mg/dL, HgbA1c %A1c, Vitamin D ng/ml, calcium mg/dL, assessed monthly |
Countries
United States
Outcome results
None listed